Source: Eur Respir J, 53 (4) 1802081; 10.1183/13993003.02081-2018
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Angelina Pieters, Marleen Bakker, Rogier A.S. Hoek, Josje Altenburg, Mireille van Westreenen, Joachim G.J.V. Aerts, Menno M. van der Eerden. The clinical impact of Pseudomonas aeruginosa eradication in bronchiectasis in a Dutch referral centre. Eur Respir J, 53 (4) 1802081; 10.1183/13993003.02081-2018

Member's Comments

No comment yet.

Related content which might interest you: The clinical impact of pseudomonas aeruginosa eradication in bronchiectasis in a Dutch center of expertise Source: International Congress 2018 – Bronchiectasis: phenotypes, endotypes and new therapies Year: 2018 The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis Source: Eur Respir J, 51 (2) 1701953; 10.1183/13993003.01953-2017 Year: 2018 Pseudomonas eradication management in COPD: results from a single centre Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Pseudomonas aeruginosa DNA-fingerprinting of colonized CF-patients in a rehabilitation centre: a 2-years survey Source: Eur Respir J 2003; 22: Suppl. 45, 174s Year: 2003 Low transmission risk of Pseudomonas aeruginosa in a bronchiectasis clinic based on the knowledge of bacterial population biology Source: Eur Respir J, 53 (3) 1802191; 10.1183/13993003.02191-2018 Year: 2019 Clinical and microbiological characteristics of Pseudomonas aeruginosa isolates from patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 58s Year: 2005 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Pseudomonas aeruginosa eradication therapy on Cystic Fibrosis- Guideline and clinical routine Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients Source: Eur Respir J 2006 Oct 01;28(4):740-747 Year: 2006 Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Source: Eur Respir J 2005; 25: 474-481 Year: 2005 Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020 Year: 2021 Eradication of pseudomonas aeruginosa in paediatric cystic fibrosis patients in Northern Ireland Source: Eur Respir J 2003; 22: Suppl. 45, 502s Year: 2003 Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Source: Eur Respir J , 49 (4)  1600851; DOI: 10.1183/13993003.00851-2016 Year: 2017 Clinical outcomes of the patients with multidrug-resistant Acinetobacter baumannii pneumonia in critical care setting: A retrospective cohort study in Taiwan Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018 DNA fingerprinting of pseudomonas aeruginosa in cystic fibrosis patients: risk assessment of cross-infection in a CF centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002 The clinical evaluation of patients with Pseudomonas aeruginosa detected in respiratory specimens Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 DNA fingerprinting of Pseudomonas aeruginosa (Pa) in cystic fibrosis patients: risk assessment of cross-colonisation in a CF revalidation centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002 Pseudomonas aeruginosa DNA-fingerprinting register in Belgian CF-patients: a one year survey Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004